论文部分内容阅读
目的了解SLE患者T淋巴细胞CD70 mRNA及其蛋白的表达情况,探讨CD70在SLE发病机理中的作用。方法用定量RT-PCR方法测定15例活动期、15例非活动期SLE患者和l5例正常人对照组外周血CD4+CD8+T淋巴细胞CD70 mRNA转录水平。用流式细胞仪检测各组的CD4+CD70+T/CD8+CD70+T淋巴细胞阳性率。结果活动期、非活动期SLE患者CD4+T淋巴细胞CD70 mRNA转录水平高于正常对照组,且活动期SLE患者CD4+T淋巴细胞的CD70mRNA转录水平高于非活动期SLE患者(P<0.05)。活动期、非活动期SLE患者CD8+T淋巴细胞CD70 mRNA转录水平与正常对照组比较差异无统计学意义(P>0.05)。活动期、非活动期SLE患者外周血CD4+CD70+T淋巴细胞阳性率高于正常对照组,且活动期SLE患者CD4+CD70+T淋巴细胞阳性率明显高于非活动期SLE患者(P<0.05)。活动期、非活动期SLE患者CD8+CD70+T淋巴细胞阳性率与正常对照组比较差异无统计学意义(P>0.05)。结论 CD4+T淋巴细胞CD70的过度表达在SLE的发生发展中可能起作用,并且CD70过度表达可以作为SLE疾病活动的一个指标。
Objective To investigate the expression of CD70 mRNA and its protein in T lymphocytes in patients with SLE and to explore the role of CD70 in the pathogenesis of SLE. Methods The transcription level of CD70 mRNA in CD4 + CD8 + T lymphocytes from peripheral blood of 15 active SLE patients, 15 inactive SLE patients and 15 normal controls were determined by quantitative RT-PCR. The positive rate of CD4 + CD70 + T / CD8 + CD70 + T lymphocytes in each group was detected by flow cytometry. Results The level of CD70 mRNA in CD4 + T lymphocytes in active and inactive SLE patients was higher than that in normal control subjects, and the level of CD70 mRNA in CD4 + T lymphocytes of active SLE patients was higher than that in inactive SLE patients (P <0.05) . The CD70 mRNA level of CD8 + T lymphocytes in active and inactive SLE patients was not significantly different from that in normal controls (P> 0.05). The positive rate of CD4 + CD70 + T lymphocytes in active and inactive SLE patients was higher than that in normal controls, and the positive rate of CD4 + CD70 + T lymphocytes in active SLE patients was significantly higher than that in inactive SLE patients (P < 0.05). The positive rates of CD8 + CD70 + T lymphocytes in active and inactive SLE patients were not significantly different from those in normal controls (P> 0.05). Conclusion Overexpression of CD70 on CD4 + T lymphocytes may play a role in the development of SLE. CD70 overexpression may be used as an indicator of SLE disease activity.